ICYMI, some of this week’s featured content includes what FDA approvals to watch for in April, trending skin care, navigating the match process, plus more.
The FDA has granted an orphan drug designation to the orally bioavailable, highly-specific G protein-coupled estrogen receptor agonist LNS8801 for the treatment of patients with metastatic uveal melanoma.
Michael A. Davies, MD, PhD, discusses how he currently approaches treatment for patients advanced BRAF-mutant melanoma as well as exciting areas of current research to address ongoing questions in the community.
This week’s edition of The Mainstream Patient features stories on facial cupping, hyperpigmentation on darker skin types, mushrooms in skincare, plus more.
In this video interview, Jay Wofford, MD, FAAD, provides some insightful tips on how to navigate the match process.
Biofrontera announces it is seeking FDA-approval for its new BF-RhodoLED XL lamp to be used in combination with topical aminolevulinic acid hydrochloride gel 10% for the treatment of actinic keratosis.
Each month, Dermatology Times® features a roundup of products trending in skin care. Click here to find out what products are trending for the month of April.
Explore the dermatologic drugs the FDA will make a decision to approve during April 2021.
The AAD announced it will begin accepting applications soon for its 2021 Hair Loss and Alopecia Initiative in Research (HAIR) Grant Program, which focuses on helping fund research for hair disorders, especially in diverse populations.